Aytu BioScience announces accelerated launch of ZolpiMist sleep aid in the U.S.

Aytu BioScience announces accelerated launch of ZolpiMist in the U.S.  Earlier today, Aytu announced the accelerated launch of ZolpiMist, an oral spray formulation of zolpidem tartrate and the only FDA-approved oral spray prescription sleep aid. The Aytu BioScience sales force begins promoting ZolpiMis to U.S. clinicians in the domestic $1.8B non-benzodiazepine prescription sleep aid market. The earlier than expected launch of ZolpiMist was made possible by the company taking early delivery of an initial supply of commercial ZolpiMist inventory. Josh Disbrow, Aytu BioScience Chief Executive Officer stated, “We are pleased to be launching ZolpiMist this week ahead of schedule, following the signing of our exclusive license agreement just two months ago. Our sales force has completed a rigorous training program, and initial inventory has been purchased and received. Additionally, U.S. wholesalers have been stocked, and now we are well positioned to effectively promote ZolpiMist alongside Natesto, our FDA-approved nasally-administered testosterone replacement therapy. ZolpiMist is a novel product, offering distinct benefits to patients with short-term insomnia, and we look forward to introducing ZolpiMist to the U.S. market.”

https://bit.ly/2MpEzZt